江中藥業(600750.SH):擬以股權轉讓及增資取得海斯製藥51%股權
格隆匯9月17日丨江中藥業(600750.SH)公佈,公司擬以股權轉讓及增資的方式收購晉城海斯製藥有限公司(“海斯製藥”)51%的股權;其中擬通過公開摘牌方式取得海斯製藥36%股權(晉能控股裝備製造集團有限公司持有的海斯製藥25.7102%股權、晉城王台科工貿有限公司持有的海斯製藥10.2898%股權);若摘牌成功,後續計劃通過增資方式將持有海斯製藥的股權比例由36%增加至51%;此次交易價款總金額預計22023.4338萬元,資金來源為公司自有資金。(最終交易價格以實際成交價格為準)
公吿顯示,海斯製藥主要從事化學藥的研製,以治療型化藥為主,具備生產生物製劑、口服固體制劑、小容量注射劑、凍乾粉針劑、膠囊劑、顆粒劑等劑型和原料藥的生產條件。公司核心產品有“貝飛達”雙歧桿菌三聯活菌腸溶膠囊、雷貝拉唑鈉腸溶片、注射用鹽酸溴已新、注射用伏立康唑等。其中,OTC 產品“貝飛達”雙歧桿菌三聯活菌腸溶膠囊為國家基藥目錄、國家醫保目錄產品,主治因腸道菌羣失調引起的急慢性腹瀉、便祕。據米內網數據,“貝飛達”雙歧桿菌三聯活菌腸溶膠囊2020 年銷售額在國內微生態製劑排名第4。
此次交易完成後,有利於藉助海斯製藥的產品豐富公司產品結構,完善公司胃腸領域業務佈局,增強雙方在品牌、產品、終端等方面的廣泛協同和資源整合,提升公司盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.